Designed for Innovation
USER-DRIVEN PRODUCT DESIGN & DEVELOPMENT
For over 40 years, HSD has been integrating insight, experience, and innovation with user needs & client core competencies to develop products that improve the human experience.
DESIGNED FOR INNOVATION
Crafting a better relationship between the product and its purpose.
Gladstone, NJ (May 4, 2017) — HS Design is pleased to announce that Canfield Scientific’s VECTRA WB360 has been selected as a finalist in the Radiological, Imaging, and Electromechanical Devices Category of the 19th Annual Medical Design Excellence Awards competition....
HSD is introducing Sympfiny™ at the 2017 BIOMEDevice Conference this week and at MD&M East Conference next month. Sympfiny™ is an innovative system for dosing and dispensing multiparticulate, dry powder, and microsphere, drug formulations for oral delivery. HSD...
From expanded indications for transcatheter aortic valve replacement systems to bioresorbable stents, medical technology took some big leaps forward in 2016. So what might 2017 have in store? We asked industry experts for some predictions. Here, in their own words,...
FDAnews’s first-ever all-day conference on combination products will feature 17 experts from from every background — drugs, devices, biologics, generics, regulatory, legal, consulting and more. Tor Alden, Principal/CEO of HSD, will be speaking as part of a panel on...
HS Design will be participating in the 2017 BIOMEDevice Conference and Exhibit on May 2nd and 3rd at the Boston Convention & Exhibit Center. Stop by booth 304 to meet our design and engineering experts discussing commercialization challenges, design trends and the latest in regulatory guidance.
HS Design will be participating in Landmark’s annual Health Innovations Forum, Thursday March 2nd at Club 101, NYC. This special industry forum will highlight advances in medical device, diagnostics and patient-centric delivery systems. Because of the unique opportunities these innovative technologies present to the market, this forum will be of particular interest to angel and family investors.